STING AGONIST-4
STING AGONIST-4 性质
| 密度 | 1.48±0.1 g/cm3(Predicted) |
|---|---|
| 储存条件 | Store at -20°C |
| 溶解度 | DMSO：微溶 |
| 形态 | 固体 |
| 酸度系数(pKa) | 11.97±0.43(Predicted) |
| 颜色 | 白色至灰色 |
| InChIKey | ICZSAXDKFXTSGL-UHFFFAOYSA-N |
| SMILES | C(N1C(NC(C2N(CC)N=C(C)C=2)=O)=NC2=CC(C(N)=O)=CC=C21)CCCN1C(NC(C2N(CC)N=C(C)C=2)=O)=NC2=CC(C(N)=O)=CC=C21 |
STING AGONIST-4 用途与合成方法
IC50: 20 nM (STING agonist-4)
STING agonist-4 (Compound 2) (0.3-30 μM; 2 hours) causes phosphorylation of IRF3 and STING that is inhibited by the TBK1 inhibitor BX795 and induces dose-dependent secretion of IFN-β with an EC 50 of 3.1 μM. STING agonist-4 (Compound 2) (0.001 nM-1 μM) inhibits binding of full-length STING to the solid support with an apparent dissociation constant (K d ) of approximately 1.6 nM. STING agonist-4 (Compound 2) (0-100 μM) is 18-fold more potent than cGAMP (an endogenous STING ligand), with an EC 50 of 53.9 μM. STING agonist-4 (Compound 2) (3 μM; 4 hours) promotes production of interferon γ-induced protein 10 (IP-10), IL-6 and TNF-α by a mechanism that is dependent on STING-mediated activation of TBK1.
Cell Viability Assay
| Cell Line: | Human peripheral blood mononuclear cells (PBMCs) |
| Concentration: | 0.3 μM, 1 μM, 3 μM, 10 μM and 30 μM |
| Incubation Time: | 2 hours |
| Result: | Caused phosphorylation of IRF3 and STING and induced secretion of IFN-β. |
STING AGONIST-4 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026-09-15 | HY-123943 | 2138300-40-8 | 1 mg | 1600 | |
| 2026-09-15 | HY-123943 | STING AGONIST-4 | 2138300-40-8 | 5mg | 3500 |
